Patients who use their semaglutide treatment window (typically 1836 months) to rebuild exercise capacity, retrain eating behaviors, and stabilize blood sugar achieve the best outcomes when transitioning off medication
P., Medeiros Araujo de Matos, U., & Fornari Caprara, A
As demand for GLP-1 weight loss injections grows, primary care teams may need stronger counselling, safety-netting and review processes
This large population-based study found that people with [IBD] who received [GLP-1 RA] medications, either for diabetes or other reasons, had a lower incidence of developing colon cancer compared to those who did not receive those medications
Though not the main aim for these clinical studies, one trial published in 2023 showed that after 16 weeks of treatment, the average weight loss was 49 lbs on danuglipron
Deficiency has also been linked with a higher likelihood of pre-eclampsia, gestational diabetes and excess weight gain during pregnancy